PensionDanmark Pensionsforsikringsaktieselskab Buys 2,700 Shares of IQVIA Holdings Inc. $IQV

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,122 shares of the medical research company’s stock after purchasing an additional 2,700 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in IQVIA were worth $5,820,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Financial Freedom LLC bought a new position in IQVIA during the first quarter worth about $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA in the 1st quarter valued at about $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $27,000. Finally, CrossGen Wealth LLC bought a new position in IQVIA during the 4th quarter worth approximately $28,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent analyst reports. TD Cowen upped their target price on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. BMO Capital Markets upped their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. Stifel Nicolaus lifted their target price on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by insiders.

IQVIA Stock Up 2.4%

Shares of IQV stock opened at $237.97 on Friday. The firm has a fifty day moving average of $200.92 and a 200-day moving average of $186.95. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The company has a market capitalization of $39.17 billion, a price-to-earnings ratio of 29.53, a P/E/G ratio of 2.03 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.